SCHEDULE 13G: Actyus Private Equity Discloses 5.45% Stake in Elicio Therapeutics
Beneficial Ownership Report
Actyus Private Equity SGIIC, S.A. has reported a 5.45% beneficial ownership stake in Elicio Therapeutics, Inc., holding 587,818 shares of common stock.
Summary
- Actyus Private Equity SGIIC, S.A. (Actyus), a Spanish investment management company, has filed a Schedule 13G indicating beneficial ownership of 587,818 shares of Common Stock in Elicio Therapeutics, Inc.
- This ownership represents 5.45% of Elicio Therapeutics' outstanding Common Stock.
- The shares are held by Azahar Private Capital, SCR, S.A., for which Actyus acts as the sole management company.
- The percentage is calculated based on 10,791,236 shares of Common Stock outstanding as of November 8, 2024, as reported in Elicio Therapeutics' Form 10Q filed on November 13, 2024.
- Actyus holds sole voting power and sole dispositive power over all 587,818 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive due to the disclosure of a new significant institutional investor, which can be interpreted as a vote of confidence. However, the document itself is purely factual and does not contain explicit positive or negative statements about the company's performance or prospects.
Positives
- A new institutional investor, Actyus Private Equity SGIIC, S.A., has taken a significant stake (5.45%) in Elicio Therapeutics, Inc., which can be interpreted as a vote of confidence in the company's prospects.
Future Outlook
NA
Industry Context
This filing indicates a new significant institutional investment in Elicio Therapeutics, a biotechnology company. Such investments can signal investor confidence in the company's pipeline or strategic direction within the competitive biotech industry.
Stakeholder Impact
- Shareholders: The entry of a new significant institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-12-08 | Date of event which required the filing of this statement (acquisition of beneficial ownership exceeding 5%). |
| 2024-11-08 | Date as of which 10,791,236 shares of Common Stock were reported outstanding in the Company's Form 10Q. |
| 2024-11-13 | Date Elicio Therapeutics, Inc. filed its Registration Statement on Form 10Q with the SEC, reporting outstanding shares. |
| 2025-01-07 | Date of signing of the Schedule 13G filing by Actyus Private Equity SGIIC, S.A. |
Keywords
Elicio Therapeutics, Actyus Private Equity, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, ELTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.